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tetracycline (96.4%) and gentamicin (99.3%). Staphylococci
included MRSA (35.7%) and MR-CoNS (68.4%); and MRSA iso-
lates were resistant to levoﬂoxacin (96%) and erythromycin
(74%). All clindamycin-susceptible SA had inducible resis-
tance. Dalbavancin (MIC90; 0.047mg/L) was 10-fold more
potent than vancomycin (MIC90; 0.5mg/L) against BHS.
Erythromycin susceptibility was 82% with a 25% inducible
clindamycin resistance.
Conclusions: The DECIDE study demonstrated in UK and
Ireland that dalbavancin has excellent activity and was more
potent when directly compared to vancomycin. Dalbavancin
was active against all MRSA, although the current suscepti-
bility proﬁles for other antimicrobial classes tested were of
great concern, particularly inducible clindamycin resistance
(100%). Monitoring dalbavancin activity should be continued
as this newer long-acting agent is introduced into EU clinical
practice.
doi:10.1016/j.ijid.2008.05.699
44.010
Dalbavancin and Selected Comparison Agents Tested
Against Indicated Gram-positive Isolates in European Med-
ical Centers (Italy): Results from the DECIDE Program
E. Debbia1, G. Nicoletti 2, G. Fadda3, D. Biedenbach4, R.
Jones4,∗
1 Osperdale S Martino, Genova, Italy
2 Azienda Policlinico Universita di Catania, Catania, Italy
3 Policlinico Agostino Gemelli, Rome, Italy
4 JMI Laboratories, North Liberty, IA, USA
Background: Dalbavancin activity was tested against iso-
lates from three medical centers in Italy between October
— December, 2007. Only reference quality and standardized
CLSI methods were used.
Methods: Susceptibility methods for agar diffusion were
applied by each investigator: Etest (ET; AB BIODISK) and
CLSI disk diffusion (DD) tests performed with concurrent QC
with repeated testing of strains showing unusual resistance
patterns such as linezolid, teicoplanin or dalbavancin-
non-susceptibility (MIC, >0.25mg/L). 225 strains were
tested against dalbavancin and teicoplanin by ET and
linezolid, cefoxitin, levoﬂoxacin, gentamicin, tetracycline,
erythromycin, clindamycin (plus D-test), penicillin and cef-
triaxone by DD. Dalbavancin susceptibility was deﬁned at
≤0.25mg/L.
Results: Dalbavancin showed high activity against the
151 S. aureus (SA; MIC range, ≤0.016—0.25mg/L), CoNS
(≤0.016—0.25mg/L) and -haemolytic streptococci (BHS;
≤0.016—0.094mg/L). This activity was 4-, 16- and ≥4-
fold greater than teicoplanin when comparing MIC90 values,
respectively. Susceptibility rates among SA were: linezolid
(97%), levoﬂoxacin (61%), erythromycin (43%), clindamycin
(51%), tetracycline (86%) and gentamicin (70%). Six linezolid-
non-susceptible strains were noted among SA and BHS but
all had zone diameters (19—20mm) near the breakpoint
(≥21mm). Teicoplanin-resistant CoNS and levoﬂoxacin-
resistant BHS were detected. A distinct trend toward higher
dalbavancin ET MIC results was observed, a probable techni-
cal reading error also noted for false-resistant DD linezolid
results for SA and BHS (six occurrences). D-test inducible-
resistant rates for clindamycin varied from 38 (BHS) to 78%
(SA).
Conclusions: Dalbavancin, a new long-acting glycol-
ipopeptide (once weekly dosing), demonstrated high activity
(MIC50 ranges, ≤0.016—0.19mg/L) against staphylococci and
BHS from Italy. The recorded MIC90 was 0.125mg/L, a con-
ﬁrmed ﬁnding suggesting a high MIC reading bias for ET. The
most elevated MIC results were at 0.25mg/L (breakpoint; 33
occurrences among SA). The exhibited dalbavancin potency
(4-fold greater than teicoplanin; only tested in Italy DECIDE
sample) covered all contemporary Gram-positive pathogens.
doi:10.1016/j.ijid.2008.05.700
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Background: Dalbavancin, a long-acting glycolipopep-
tide, was tested against clinical isolates from four hospitals
in Germany in the last quarter of 2007.
Methods: Investigators used standardized and reference-
quality agar diffusion methods including Etest (ET; AB
BIODISK) and CLSI disk diffusion (DD) tests with concur-
rent QC and repeated testing of strains showing unusual
resistance patterns such as linezolid resistance and van-
comycin or dalbavancin-non-susceptibility. 300 strains were
tested (200 S. aureus [SA], 40 coagulase-negative staphy-
lococci [CoNS], 60 -haemolytic streptococci [BHS] with
most being group A or S. pyogenes) against dalbavancin and
vancomycin by ET; and linezolid, cefoxitin (determination
of methicillin resistance), levoﬂoxacin, gentamicin, tetra-
cycline, erythromycin, clindamycin (plus D-test), penicillin
and ceftriaxone by DD. All German sites having acceptable
QC results were tabulated. Dalbavancin susceptibility was
deﬁned at ≤0.25mg/L.
Results: Dalbavancin exhibited excellent activity
against SA (MIC50/90, 0.047/0.125mg/L), CoNS (MIC50/90,
0.047/0.19mg/L) and BHS (MIC50/90, ≤0.016/0.032mg/L).
This activity was 16- to 32-fold greater than vancomycin.
MRSA rates were low (8%) but varied modestly from 4
to 12% among hospitals. S rates were: linezolid (100%),
levoﬂoxacin (55-83%), erythromycin (50—80%), and clin-
damycin (65—84%). D-test positive rates were 33—86% for
the SA, CoNS and BHS; overall clindamycin-resistant at
16% for SA, but nil for BHS. SA was also very susceptible
to gentamicin (95%) and tetracycline (93%). Methicillin
susceptibility or resistance did not inﬂuence dalbavancin
potency versus SA or CoNS. Highest recorded dalbavancin
MIC was 0.38mg/L, two conﬁrmed staphylococci from
Frankfurt. Some German centers read Etest results higher
(0.5—1.0 log2) than other laboratories in Europe.
